<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16629">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01903109</url>
  </required_header>
  <id_info>
    <org_study_id>CEVI-C30-PVFD-1</org_study_id>
    <nct_id>NCT01903109</nct_id>
  </id_info>
  <brief_title>Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions</brief_title>
  <official_title>A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roxane Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roxane Laboratories</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to prove the bioequivalence of  Roxane Laboratories'
      Cevimeline 30 mg under fed conditions
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>bioequivalence determined by statistical comparison Cmax</measure>
    <time_frame>33 Days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Dry Mouth</condition>
  <arm_group>
    <arm_group_label>Cevimeline first, the Evoxac</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose 30 mg cevimeline capsule, then single dose 30 mg Evoxac capsule (after washout period)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>First Evoxac, then cevimeline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose 30 mg Evoxac capsule, then single dose 30 mg cevimeline capsule (after washout period)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cevimeline</intervention_name>
    <arm_group_label>Cevimeline first, the Evoxac</arm_group_label>
    <arm_group_label>First Evoxac, then cevimeline</arm_group_label>
    <other_name>Evoxac</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - No clinically significant abnormal findings on the physical examination, medical
        history, or clinical laboratory results during screening

        Exclusion Criteria:

          -  Positive test for HIV, Hepatitis B, or Hepatitis C.

          -  Treatment with known enzyme altering drugs.

          -  History of allergic or adverse response to cevimeline or any comparable or similar
             product.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darin Brimhall, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novum Pharmaceutical Research Services</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novum Pharmaceutical Research Services</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 26, 2013</lastchanged_date>
  <firstreceived_date>July 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cevimeline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
